Next Article in Journal
Evaluation of Triggered Electromyogram Monitoring during Insertion of Percutaneous Pedicle Screws
Next Article in Special Issue
Increased Prognostic Yield by Combined Assessment of Non-Contrast Computed Tomography Markers of Antithrombotic-Related Spontaneous Intracerebral Hemorrhage Expansion
Previous Article in Journal
Catamenial Pneumothorax as the First Expression of Thoracic Endometriosis Syndrome and Pelvic Endometriosis
Previous Article in Special Issue
New Candidates for Biomarkers and Drug Targets of Ischemic Stroke—A First Dynamic LC-MS Human Serum Proteomic Study
Article

Platelet-Derived Drug Targets and Biomarkers of Ischemic Stroke—The First Dynamic Human LC-MS Proteomic Study

1
Department of Neurology, 4th Military Hospital, Weigla 5, 50-556 Wroclaw, Poland
2
Department of Internal Medicine, Hypertension and Clinical Oncology, Faculty of Medicine, Wroclaw Medical University, Borowska 213 Str., 50-556 Wroclaw, Poland
3
Lower Silesian Centre for Lung Diseases, Grabiszyńska 1 Str., 53-439 Wroclaw, Poland
4
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego Str., 02-106 Warsaw, Poland
5
Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Chałubińskiego Str., 50-345 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Georgios Tsivgoulis
J. Clin. Med. 2022, 11(5), 1198; https://doi.org/10.3390/jcm11051198
Received: 20 January 2022 / Revised: 15 February 2022 / Accepted: 21 February 2022 / Published: 23 February 2022
(This article belongs to the Special Issue New Frontiers in the Clinical Management of Stroke)
(1) Objective: The aim of this dynamic LC-MS (liquid chromatography and mass spectrometry) human platelet proteomic study was to identify the potential proteins candidates for biomarkers of acute ischemic stroke (AIS), their changes during the acute phase of stroke and to define potential novel drug targets. (2) Methods: A total of 32 patients (18–80 years old) were investigated that presented symptoms of AIS lasting less than 24 h from the onset, confirmed by neurological examination and/or new cerebral ischemia visualized in the CT (computed-tomography) scans. The analysis of platelet proteome was performed using LC-MS at baseline, and then on the third and seventh day from the onset of symptoms. The control group was demographically matched without any clinical signs of acute brain injury. (3) Results: The differences between platelets, at 24 h after first symptoms of stroke subjects and the control group included: β-amyloid A4 and amyloid-like protein 2, coactosin-like protein, thymidine phosphorylase 4 (TYMP-4), interferon regulatory factor 7 (IRF7), vitamin K-dependent protein S, histone proteins (H2A type 1 and 1-A, H2A types 2B and J, H2Av, -z, and -x), and platelet basic protein. The dynamic changes in the platelet protein concentration involved thrombospondin-1, thrombospondin-2, filamin A, B, and C. (4) Conclusions: This is the first human dynamic LC-MS proteomic study that differentiates platelet proteome in the acute phase of ischemic stroke in time series and compares the results with healthy controls. Identified proteins may be considered as future markers of ischemic stroke or therapeutic drug targets. Thymidine phosphorylase 4 (TYMP-4) holds promise as an interesting drug target in the management or prevention of ischemic stroke. View Full-Text
Keywords: stroke; platelet proteome; biomarkers; platelets; thymidine phosphorylase 4; proteomics; drug target; human stroke; platelet proteome; biomarkers; platelets; thymidine phosphorylase 4; proteomics; drug target; human
Show Figures

Figure 1

MDPI and ACS Style

Gawryś, K.; Turek-Jakubowska, A.; Gawryś, J.; Jakubowski, M.; Dębski, J.; Szahidewicz-Krupska, E.; Trocha, M.; Derkacz, A.; Doroszko, A. Platelet-Derived Drug Targets and Biomarkers of Ischemic Stroke—The First Dynamic Human LC-MS Proteomic Study. J. Clin. Med. 2022, 11, 1198. https://doi.org/10.3390/jcm11051198

AMA Style

Gawryś K, Turek-Jakubowska A, Gawryś J, Jakubowski M, Dębski J, Szahidewicz-Krupska E, Trocha M, Derkacz A, Doroszko A. Platelet-Derived Drug Targets and Biomarkers of Ischemic Stroke—The First Dynamic Human LC-MS Proteomic Study. Journal of Clinical Medicine. 2022; 11(5):1198. https://doi.org/10.3390/jcm11051198

Chicago/Turabian Style

Gawryś, Karolina, Aleksandra Turek-Jakubowska, Jakub Gawryś, Maciej Jakubowski, Janusz Dębski, Ewa Szahidewicz-Krupska, Małgorzata Trocha, Arkadiusz Derkacz, and Adrian Doroszko. 2022. "Platelet-Derived Drug Targets and Biomarkers of Ischemic Stroke—The First Dynamic Human LC-MS Proteomic Study" Journal of Clinical Medicine 11, no. 5: 1198. https://doi.org/10.3390/jcm11051198

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop